Abstracts tagged "Systemic sclerosis"

Abstract Number: 2364 • ACR Convergence 2023
Circulating CTHRC1 Levels Are Associated with Disease Severity and Predict Survival in Systemic Sclerosis
Monica Yang¹, Seoyeon Lee², Lisa Hazelwood³, Dean Sheppard¹, Francesco Boin⁴ and Paul Wolters¹, ¹University of California San Francisco, San Francisco, CA, ²Yale University School of Medicine, New Haven, CT, ³AbbVie, Inc., North Chicago, IL, ⁴Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Despite recent advances in systemic sclerosis (SSc), there remains a paucity of clinically actionable biomarkers to assess disease severity and predict progression. Collagen triple…
Abstract Number: 0616 • ACR Convergence 2023
Does Systemic Sclerosis Affect the Interpretation of Mammograms? A Retrospective Cohort Study
Lea Meir¹, Tegveer Sandhu², Weiwei Chi² and Gabriela Santiago², ¹Icahn School of Medicine, New York, NY, ²Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Systemic Sclerosis is an autoimmune disorder marked by thickened and hardened skin. Cutaneous cutis, the deposition of insoluble calcium salts in the skin and…
Abstract Number: 0634 • ACR Convergence 2023
Prevalence and Associations of Anaemia in Systemic Sclerosis Patients in a National Observational Cohort; Results from the Australian Scleroderma Cohort Study
Raychel Barallon¹, Gene-Siew Ngian¹, Diane Apostolopoulos¹, Dylan Hansen², Kathleen Morrisroe³, Wendy Stevens⁴, Susanna Proudman⁵, Mandana Nikpour⁶ and Joanne Sahhar¹, ¹Monash Health and Monash University, Clayton, Australia, ²Department of Rheumatology, St Vincent’s Hospital Melbourne, Fitzroy, Australia, ³The University of Melbourne at St Vincent’s Hospital Melbourne, Fitzroy, Australia, ⁴Department of Rheumatology, St Vincent's Hospital Melbourne, Fitzroy, Australia, ⁵Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia, ⁶The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia
Background/Purpose: Anaemia in systemic sclerosis (SSc) is under-studied and under-characterised. Its prevalence amongst SSc patients is not well described, nor are its effects on outcomes…
Abstract Number: 0657 • ACR Convergence 2023
The Value of the Six-Minute Walk Test in Detecting Cardiopulmonary Involvement in Patients with Systemic Sclerosis
Saad Ahmed, Sophie Liem, Jeska de Vries-Bouwstra and Thomas Huizinga, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Cardiopulmonary involvement (CPI) in systemic sclerosis (SSc) is associated with significant morbidity and mortality. Early detection and timely treatment is warranted. The Six-minute walk…
Abstract Number: 0791 • ACR Convergence 2023
Expression of TL1A, Inflammatory, and Fibrotic Pathways in Patients with Diffuse Systemic Sclerosis
Heather Llewellyn¹, Lam (Alex) Tsoi², Minghua Wu³, Kristina Grigaityte¹, Tony (Yong) Wang¹, James R. Seibold¹, Ernesto Muñoz-Elias¹, Dinesh Khanna⁴ and Johann E. Gudjonsson⁴, ¹Prometheus Biosciences, Inc., San Diego, CA, ²Department of Dermatology and Biostatistics, University of Michigan, Ann Arbor, MI, ³Department of Internal Medicine, Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁴University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is a multiorgan disease characterized by systemic vascular injury, inflammation, and fibrosis. While SSc mainly affects the skin, pulmonary manifestations such…
Abstract Number: 0953 • ACR Convergence 2023
Flavin-containing Monooxygenase (FMO3) Links the Gut and Fibrosis in Systemic Sclerosis
Priyanka Verma¹, Bharath Yalavarthi¹, Karen Ho², Lutfiyya Muhammad³, Seokjo Kim⁴, Johann Gudjonsson¹, Rebecca C Schugar⁵, Mark Brown⁶, Xinmin Li⁶, Stanley L Hazen⁷, Swati Bhattacharyya¹ and John Varga¹, ¹University of Michigan, Ann Arbor, MI, ²Northwestern University, Chicago, IL, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴4SCM Lifescience Co. Ltd, South Korea, Japan, ⁵Stanford University, Stanford, CA, ⁶Department of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, ⁷Division of Endocrinology, Department of Medicine, Stanford University, Stanford, CA
Background/Purpose: Trimethylamine (TMA) generated by the gut microbiome is converted into trimethylamine N-oxide (TMAO) via the host enzyme FMO3. The TMA-FMO3-TMAO metaorganismal axis has been…
Abstract Number: 1520 • ACR Convergence 2023
Identifying Core Domains for Clinical Trials in Systemic Sclerosis-Associated Raynaud’s Phenomenon and Digital Ulcers Using the Delphi Consensus Method
Susanna Proudman¹, Michael Hughes², Nancy Maltez³, Edith Brown⁴, Virginia Hickey⁵, shawna grosskleg⁶, B Shea⁶, Ariane Herrick⁷, John Pauling⁸ and Peter Merkel⁹, ¹Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia, ²Northern Care Alliance NHS Foundation Trust, Salford Care Organisation, Salford, United Kingdom, ³Department of Medicine, Division of Rheumatology, The Ottawa Hospital, Ottawa, ON, Canada, ⁴OMERACT, Manchester, United Kingdom, ⁵OMERACT, Adelaide, Australia, ⁶OMERACT, Ottawa, ON, Canada, ⁷University of Manchester, Salford, United Kingdom, ⁸North Bristol NHS Trust, Bristol, United Kingdom, ⁹University of Pennsylvania, Philadelphia, PA
Background/Purpose: The OMERACT Scleroderma Vascular Disease Working Group sought to identify essential core outcome domains for inclusion in clinical trials focusing on Raynaud's phenomenon (RP)…
Abstract Number: 1701 • ACR Convergence 2023
Treatment Regimens and Mortality in Systemic Sclerosis-associated Pulmonary Arterial Hypertension in Light of the 2022 ESC/ERS Guidelines
Hilde Jenssen Bjørkekjær¹, Cosimo Bruni², Cathrine Brunborg³, Patricia Carreira⁴, Paolo Airò⁵, Carmen Pilar Simeon-Aznar⁶, Marie-Elise Truchetet⁷, Alessandro Giollo⁸, Alexandra Balbir-Gurman⁹, Mickael Martin¹⁰, Christopher Denton¹¹, Armando Gabrielli¹², Havard Fretheim¹³, Imon Barua¹³, Helle Bitter¹⁴, Oyvind Midtvedt¹³, Torhild Garen¹⁵, Kaspar Broch¹⁶, Arne Andreassen¹⁷, Yoshiya Tanaka¹⁸, Gabriela Riemekasten¹⁹, Ulf Müller-Ladner²⁰, marco Matucci Cerinic²¹, Iván Castellvi²², Elise Siegert²³, Eric Hachulla²⁴, Oliver Distler² and Anna-Maria Hoffmann-Vold¹³, ¹Department of Rheumatology, Hospital of Southern Norway, Kristiansand & University of Oslo, Institute of Clinical Medicine, Oslo, Norway, ²Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ³Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, ⁴Hospital Universitario 12 de Octubre, Madrid, Spain, ⁵Spedali Civili di Brescia, Scleroderma UNIT, UOC Reumatologia ed Immunologia Clinica, Piazzale Spedali Civili 1, 25123, Brescia, Italy, ⁶Department of Internal Medicine, Systemic Autoimmune Diseases Unit, Hospital Universitario Vall d'Hebronh, Barcelona, Spain, ⁷Bordeaux University Hospital, Bordeaux, France, ⁸University of Verona, Rheumatology Section, Department of Medicine, Verona, Italy, Verona, Italy, ⁹Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, ¹⁰Department of Internal Medicine, INSERM U1313, Poitiers University, Poitiers University Hospital, Poitiers, France, ¹¹University College London, London, United Kingdom, ¹²Ospedali Riuniti Marche, Ancona, Italy, ¹³Oslo University Hospital, Oslo, Norway, ¹⁴Sorlandet sykehus, Kristiansand, Norway, ¹⁵Dept of Rheumatology, University Hospital Oslo, Oslo, Norway, ¹⁶Oslo University Hospital, Rikshospitalet, Department of Cardiology, Oslo, Norway, KG Jebsen center, Institute for Experimental Medical Research, University of Oslo, Oslo, Norway, ¹⁷Oslo University Hospital, Rikshospitalet, Department of Cardiology, Oslo, Norway, ¹⁸University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁹University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, ²⁰Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, ²¹Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ²²Hospital de Santa Creu i Sant Pau, Barcelona, Spain, ²³Department of Rheumatology, Charité University Hospital, Charité Platz 1, D-10117, Berlin, Germany, ²⁴University of Lille, Lille, France
Background/Purpose: The 2022 ESC/ERS Guidelines recommend upfront combination therapy for low- and intermediate-risk, and triple therapy for high-risk patients with systemic sclerosis (SSc)-associated pulmonary arterial…
Abstract Number: 2365 • ACR Convergence 2023
Decoding the Peripheral Immune Landscape of Systemic Sclerosis to Investigate Disease Stages and Interstitial Lung Disease Progression
Vasuki Ranjani Chellamuthu¹, Maria Noviani², Ahmad bin Mohamed Lajam¹, Andrea Hsiu Ling Low² and Salvatore Albani¹, ¹Translational Immunology Institute, SingHealth, Singapore, Singapore, ²Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore
Background/Purpose: Systemic sclerosis (SSc) is a heterogenous autoimmune disease characterized by fibrosis, vascular abnormalities and immune dysregulation. Characterization of peripheral blood immune signatures in relation…
Abstract Number: 0618 • ACR Convergence 2023
Incident versus Prevalent Interstitial Lung Disease in Systemic Sclerosis in the EUSTAR Database: Different Disease Phenotypes and Prognosis
liubov Petelytska¹, Arthiha Velauthapillai², Lorenzo Tofani³, Patricia Carreira⁴, Giovanna Cuomo⁵, Eric Hachulla⁶, Ivan Castellvi⁷, Radim Becvar⁸, Alexandra Balbir-Gurman⁹, Paolo Airò¹⁰, Irena Litinsky¹¹, Lesley Ann Saketkoo¹², Madelon Vonk¹³, Jeska de Vries-Bouwstra¹⁴, Anna Maria Hoffmann-Vold¹⁵, marco Matucci Cerinic¹⁶, Oliver Distler¹⁷ and Cosimo Bruni¹⁷, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Department of Statistics, Computer Science, Applications, University of Florence, Florence, Italy, ⁴Hospital Universitario 12 de Octubre, Madrid, Spain, ⁵Department of Precision Medicine, “Luigi Vanvitelli” University of Campania, Naples, Italy, ⁶University of Lille, Lille, France, ⁷Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, ⁸Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Praha, Czech Republic, ⁹Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, ¹⁰Spedali Civili di Brescia, Scleroderma UNIT, UOC Reumatologia ed Immunologia Clinica, Piazzale Spedali Civili 1, 25123, Brescia, Italy, ¹¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ¹²University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA, ¹³Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁴Leiden University Medical Center, Leiden, Netherlands, ¹⁵Oslo University Hospital, Department of Rheumatology, Oslo, Norway, ¹⁶Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ¹⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: Although 50% of patients with systemic sclerosis (SSc) present with interstitial lung disease (ILD) at baseline, new onset of ILD can also occur later…
Abstract Number: 0636 • ACR Convergence 2023
Chasing Pain: Investigating Somatosensory Profiles in Patients with Rheumatological Diseases Using Quantitative Sensory Testing
Claus Juergen Bauer¹, Ruth Sophie Schrapper², Simon Petzinna³, Charlotte Behning⁴, Tim T.A. Bender⁵, Peter Brossart¹, Martin Muecke⁶ and Valentin Sebastian Schäfer¹, ¹Clinic of Internal Medicine III, Department of Oncology, Hematology, Rheumatology and Clinical Immunology, University Hospital of Bonn, Bonn, Germany, ²University of Bonn, Bonn, Germany, ³Clinic of Internal Medicine III, Oncology, Hematology, Rheumatology and Clinical Immunology, University Hospital Bonn, Bonn, Germany, ⁴Institute of Medical Biometry, Informatics and Epidemiology, University Hospital of Bonn, Bonn, Germany, ⁵University Hospital of Bonn, Bonn, Germany, ⁶Universital Hospital of Aachen, Aachen, Germany
Background/Purpose: Pain is a prominent symptom in numerous rheumatological diseases. In order to allow for a standardized quantification and the assessment of nociceptive and non-nociceptive…
Abstract Number: 0658 • ACR Convergence 2023
Evaluating the Associations Between Autonomic Dysfunction, Clinical Phenotype and Gastrointestinal Transit in Patients with Systemic Sclerosis
Maria Paula Alvarez Hernandez¹, Brittany Adler², Jamie Perin³, Michael Hughes⁴ and Zsuzsanna McMahan⁵, ¹Hospital Clinico San Carlos, Madrid, Spain, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Northern Care Alliance NHS Foundation Trust, Salford Care Organisation, Salford, United Kingdom, ⁵Johns Hopkins Rheumatology, Lutherville, MD
Background/Purpose: The gastrointestinal (GI) tract is the second most commonly impacted organ in systemic sclerosis (SSc). However, the pathogenesis and clinical expression of GI involvement…
Abstract Number: 0827 • ACR Convergence 2023
Development and Initial Validation of a Brief Measure of Uncertainty in Rheumatic Disease
Caleb Bolden¹, Claire Cook¹, Lucy Finkelstein-Fox¹, Xiaoqing Fu¹, Flavia Castelino¹, Hyon K. Choi², Cory Perugino¹, John Stone³, Elyse Park¹, Zachary Wallace⁴ and Daniel Hall¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital and Harvard Medical School, Lexington, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA, ⁴Massachusetts General Hospital, Newton, MA
Background/Purpose: Patients with systemic autoimmune rheumatic disease (SARD) are often tasked with monitoring ambiguous and unpredictable physical symptoms on their own. Higher levels of uncertainty…
Abstract Number: 0954 • ACR Convergence 2023
Non-canonical WNTA Promotes Cytoskeletal Rearrangement and Integrin Alpha V Clustering via JNK and ROCK to Control the Activation of Latent TGFβ
Thuong Trinh-Minh¹, Chih-Wei Chen², Cuong Tran Manh¹, yi-nan Li¹, Honglin Zhu³, Debomita Chakraborty⁴, Yun Zhang¹, Simon Rauber⁵, Clara Dees⁵, Christina Bergmann⁶, Alexander Kreuter⁷, Christiane Reuter⁸, Florian Groeber-Becker⁸, Beate Eckes⁹, Oliver Distler¹⁰, Andreas Ramming¹¹, Georg Schett¹² and Joerg Distler¹, ¹Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, ²3 Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany. 4 Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, ³3 Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany. 4 Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany. 5 Department of Rheumatology, Xiangya Hospital, Central South University, Changsha, China, ⁴3 Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany. 4 Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁵3 Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany. 4 Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, ⁶Department Internal Medicine, University Hospital Erlangen, Germany, Erlangen, Germany, ⁷Clinic for Dermatology, Venereology and Allergology, HELIOS St. Elisabeth Clinic, Oberhausen, Germany, ⁸Translational Center for Regenerative Therapies, Fraunhofer Institute for Silicate Research (ISC) Würzburg, Würzburg, Germany, ⁹Translational Matrix Biology, University of Cologne, Cologne, Germany. 9 Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Köln, Germany, ¹⁰Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany; Deutsches Zentrum für Immuntherapie, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ¹²Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disorder with vasculopathy, inflammation, and fibrosis of the skin and organs. Fibrosis is caused by the abnormal…
Abstract Number: 1522 • ACR Convergence 2023
Treatment of Pulmonary Arterial Hypertension in Patients with Connective Tissue Diseases: A Meta-analysis
Mustafa Erdogan¹, Sinem Nihal Esatoglu², Burcak Kilickiran Avci³ and Gulen Hatemi², ¹Marmara University - Pendik Training and Research Hospital, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Department of Cardiology, Istanbul, Turkey
Background/Purpose: Treatment options for pulmonary arterial hypertension (PAH) have expanded in the last two decades. However, evidence for the treatment of connective tissue disease-associated PAH…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].